CeraPedics (Lakewood, CO) developing products for the orthopedic bone substitute market announced the close of a $12.25M private equity financing from OrbiMed Advisors. The Company’s products utilize a proprietary small peptide called P-15™. This peptide has been identified to play a role in initiating the formation of bone. CeraPedics’ products may provide a safe, efficacious, and economical alternative to autograft and recombinant bone growth factor products for most procedures requiring a bone graft including spine fusion, trauma, and joint reconstruction. CeraPedics’ first product, P-15 Putty, is currently under an Investigational Device Exemption (IDE) clinical investigation for FDA regulatory approval.